Linden Capital Partners, a Chicago-based private equity firm, completed the acquisition of Alcresta Therapeutics, a provider of novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Financial terms were not disclosed. "I am very excited to join the Alcresta team to support the continuing growth of the company. Alcresta's rapid progress has made a meaningful difference for patients living with rare diseases that struggle with fat malabsorption. Linden feels very fortunate to partner with Alcresta as it prepares for new levels of momentum and success in the years ahead," Ron Labrum, Linden Operating Partner.